• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 19 Dec

    Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

    ASHBURN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion… Read More..

    Share this:
  • 18 Dec

    Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

    HOUSTON, December 18, 2024--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with… Read More..

    Share this:
  • 17 Dec

    American Shared Hospital Services Announces Official Notice of Certificate of Need Approval to Acquire the Technology to Construct and Operate a Proton Beam Radiation Therapy Facility in the State of Rhode Island

    SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the “Company” or “AMS”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that its wholly owned subsidiary, ASHS – Rhode Island Proton… Read More..

    Share this:
« Previous 1 … 34 35 36 37 38 … 239 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact